Analyst consensus rating
Cullinan Therapeutics Analyst Rating: Strong Buy
Direct answer
Cullinan Therapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.45.
Forecast evidence checked October 1, 2026.
Get free Cullinan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.35
- Average price target
- $33.45
- High price target
- $42.00
- Low price target
- $23.00
- Low target gap
- +49.8%
- Target upside
- +117.9%
- High target gap
- +173.6%
- Target range width
- 123.8%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- October 1, 2026
- Valid through
- October 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cullinan Therapeutics?
Cullinan Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $33.45.
How far are Cullinan Therapeutics's low and high targets from the recorded price?
The low target implies +49.8%, while the high target implies +173.6%.
How many analysts are included in Cullinan Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Cullinan Therapeutics's target upside or downside calculated?
The average target of $33.45 is divided by the recorded price of $15.35, then one is subtracted to produce +117.9%. This does not guarantee a future return.
When was Cullinan Therapeutics's analyst forecast verified?
The data was verified on 2026-10-01. The dataset is valid through 2026-10-08.